MREO

Mereo BioPharma Group plc (MREO) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Overall Score

Pricing Power

No evidence of pricing power: margins are 0% across gross, operating, EBITDA, pretax, and net profit margins TTM.

Revenue per share is 0, so there is no demonstrated ability to monetize products at scale.

Scale Advantages

The company remains very small with a market cap of about $42.7M, limiting any scale-based moat.

Asset and turnover metrics are effectively zero, indicating no operating scale efficiency yet.

Switching Costs

No evidence of customer lock-in or recurring revenue durability in the current metrics.

Zero revenue and zero operating margins suggest switching costs are not yet observable.

Intangible Assets

Intangible assets are minimal at roughly 0.7% of total assets, offering little moat support.

No R&D or brand-related operating evidence appears in the current financial profile.

Cost Advantage

There is no sign of a cost advantage because operating profitability is absent and cash flow is negative.

High days payable outstanding may reflect working-capital timing rather than a durable supplier advantage.

Network Effects

No network-effect indicators are visible in the financial data.

The business shows no revenue base or user growth metrics that would support a network moat.

Efficient Scale

The company is still too small to infer efficient-scale benefits from the data.

Negative returns on capital and zero margins indicate no evidence of niche dominance.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →